Adam Stern joined ThinkEquity in February 2026 as Head of Private Equity, Merchant & Venture Banking (MVB).

Adam Stern specializes in providing principal investment capital and strategic advisory services to high-growth private companies across the technology, life sciences, and emerging growth sectors.

Adam is recognized for his extensive background in venture capital, private equity, and investment banking, bringing decades of experience and a proven track record of securing funding for disruptive enterprises globally.

Adam’s Wall Street career began in 1987. Throughout his career, Adam has established merchant and venture banking divisions in multiple firms, including growing existing divisions in firms such as Josephthal & Company, and Spencer Trask Ventures. Most recently, Adam was CEO of SternAegis Ventures and Head of Private Equity Banking at Aegis Capital Corp. since 2012.

Mr. Stern has been a founding investor in numerous private and public companies and currently serves as a board member on multiple public and private companies. Adam hold Series 7, 8, 9, 10, 24, 63 and 79 licenses. Mr. Stern graduated from the Lear School, Miami Florida in 1982 and The University of South Florida in 1987.

Daniel Seto joined ThinkEquity in February 2026 as Managing Director, Private Equity, Merchant and Venture Banking (MVB).

Mr. Seto has approximately 20 years of experience in the financial services industry across investment banking, portfolio management, and equity research. Previously, he was Senior Vice President at ArcLight Advisors LLC providing investment banking and business development services focused on healthcare companies. Prior to that, he was Vice-President in investment banking at Ledgemont Capital Group.

From 2004-2008, Mr. Seto was a Portfolio Manager for Wheaten Capital Management LLC, a long/short equity healthcare hedge fund. As Portfolio Manager, Mr. Seto invested in both public and private companies across all subsectors of healthcare, including pharmaceuticals, biotechnology, medical technology, life science tools, and healthcare services. From 1999-2003, Mr. Seto was an equity analyst at Bank of America Securities covering the Specialty Pharmaceuticals industry. Mr. Seto started his career in equity research at UBS covering the Specialty Pharmaceuticals industry.

Mr. Seto's academic credentials include designation as a Chartered Financial Analyst and a B.A. in Economics from the University of Michigan.

John Clarke joined ThinkEquity as Managing Director, Private Equity, Merchant and Venture Banking (MVB).

Mr. Clarke has over 35 years of experience providing specialty financing and capital advice regarding emerging private and public companies. Previously, he has been President of H.C. Wainwright & Co and worked with Spencer Trask Ventures, as well as several Investment boutiques and NYSE brokerage firms. During his career, he has raised several hundred million dollars for over 100 private and public Offerings in a variety of emerging industries. 

Mr. Clarke developed his career as a Branch Manager for Josepthal, Lyon & Ross and is currently registered with Representative, General Securities and Financial and Operations Principal Securities licenses. He is a graduate of the E. Claiborne Robbins School of Business and holds a B.S. in Finance, and lives in New Jersey.

Jamie Polak joined ThinkEquity in February 2026 as a Managing Director & Controller, Private Equity, Merchant and Venture Banking (MVB). Mr. Polak has extensive experience in financial modeling, securities valuation, asset allocation, and risk management.

Since 2007, Mr. Polak has worked as a research analyst for the hedge fund RL Capital partners, a multi-strategy growth hedge fund. At RL Capital, Mr. Polak focused on investment analysis and portfolio management, with an emphasis on small and mid-cap biotechnology companies.

Mr. Polak is also a general partner of a venture capital fund called Domaco Venture Capital Fund, focusing on private placement investments and fund administration.

Prior to ThinkEquity, Mr. Polak was with Maxim Group, where he focused his research on small to mid-cap U.S. listed equities. He also worked as a multimedia producer for Bloomberg L.P., providing analysis and reporting for the Bloomberg terminals. Mr. Polak started his career as an Equity Research Associate for Gruntal & Co. L.L.C., specializing in Internet Software and Biotechnology companies in the early 2000s. Mr. Polak holds a BBA from the George Washington University and an MBA from the Smith School of Business at the University of Maryland. He is a CERTIFIED FINANCIAL PLANNER™ and holds FINRA series 7, 63, 24, and 16 licenses.

Solar Tech is a leading solar company on a mission to change lives through affordable clean energy, that has been designing and building solar systems since 2001. Our targeted approach is designed to reach those who are actively seeking solar solutions, ensuring that our efforts and resources are focused where they matter most. Our core belief is that by reducing energy costs, we open the door to more opportunities for individuals and families.  

This means more resources for the things that truly matter – creating “more room for good” in people’s lives. We’re committed to making clean energy not just a choice, but an accessible and affordable reality for everyone we serve.

Prometheum is a Delaware corporation formed in September 2017 for the purpose of developing, building out and commercializing a trading ecosystem (“Trading Ecosystem”) for Digital Asset Securities. Our proprietary technology integrates the requirements and investor protections of federal securities laws and regulations with the efficiencies of distributed ledger technology. Through our SEC registered and FINRA member broker-dealer subsidiaries, we offer a unique solution to retail investors and institutions seeking to participate in the digital asset economy.

Amplifica is a biopharmaceutical company focused on developing novel treatments to address androgenic alopecia (hair loss), a condition estimated to affect over 50 million men and over 30 million women in the United States alone. The Company has identified and isolated unique signaling molecules that stimulate hair follicles to regrow hair. Amplifica will be initiating clinical trials to evaluate the safety and efficacy of its core technology as well as obtaining all applicable regulatory approvals.

Aeropost is a logistics technology company committed to innovating the cross-border logistics experience. Aeropost is the prominent player in the Latin American and the Caribbean markets, supporting millions of consumers, businesses, retailers, and marketplaces in their cross-border logistics needs.

Aeropost's roots trace back to the early 90s when we first started providing a logistics solution for US expatriates in Costa Rica. Today, we have evolved into an asset-based vertically integrated logistics solution provider for Latin America and the Caribbean, offering end-to-end services for cross-border purchases, payments, and deliveries in over 30+ countries.

We have a deep understanding of our customers and the unique demands of each market. From duty calculation and customs clearance to international shipping and last-mile delivery, Aeropost's expertise is unrivaled. Our local presence is prominent, with business entities, staff, assets, infrastructure, customer service, branded retail shops, lockers and an innovative local payments platform that facilitates purchases from US retailers.

Laconic's mission is to deliver accurate environmental intelligence, tools, and insights – in harmony with our company values – enabling governments, corporations, and financial institutions to engage equitably in seamless data interchange so that carbon instruments can be traded at scale in global financial markets.  The SADAR™ NCM platform provides the much-needed immutable datastore and structured information interchange required for carbon markets to function properly. For the first time, all carbon market participants, now have access to the right information at the right time – meeting the liquidity and compliance requirements for trading at scale in global financial markets. The Laconic SADAR™ (Sentient All-Domain Augmented Response) technology stack gets its name from the Bahasa Indonesia word for “awareness”. Built natively on the cloud for unlimited scalability, the SADAR™ stack ingests vast amounts of disparate structured and unstructured data from geospatial, jurisdictional authority, and financial data sources. The data is organized into one single data stream for easy integration into existing financial and business process flows. Outlier noises are eliminated, and valuable signals are brought to light.

ZoomCar is a developer of an online platform used to offer self-drive car rental services. It is a self-drive-focused car rental company allowing individuals to rent vehicles by the hour, day, and week. Its platform offers a wide range of cars ranging from hatchbacks to SUVs, sedans, and luxury on rent for hourly, daily, and weekly basis at all-inclusive prices that enable users to book cars using their mobile phones and travel as per their plans in a hassle-free manner.

Orchestra BioMed (OBIO) is a therapeutic device company focused on the development and commercialization of high impact, data-driven, transformational solutions for targeted high value unmet medical needs. 

Orchestra BioMed Proposed Merger

Outstanding Foods was founded on a simple idea: To create addictively delicious plant-based foods that anyone can love. How are Outstanding Foods so full of flavor and free of guilt? One bite will tell you. The team keeps it real with pure, wholesome ingredients – and nothing from animals or artificial ingredients. To top it off, every product in the lineup is carefully prepared for you by Chef Dave with his proprietary chef-crafted methods. He won’t let anything leave his kitchen until it tastes absolutely outstanding!

Aegis Special Situations Fund LLC, Aegis Special Situations Fund II LLC, and Aegis Special Situations QP Fund LLC (together, the "Fund") are Delaware series limited liability companies created for the purpose of making and managing investments in mid- or late-stage pre-IPO technology and services companies (each an “Issuer” and collectively the “Issuers”). The Fund intends to purchase securities of Issuers ("Issuer Securities”) from shareholders of Issuers in so-called “secondary market transactions,” directly from Issuers in one or more direct private placement transactions and may invest indirectly in the appreciation of Issuer Securities by investing in entities that hold underlying Issuer Securities, forward contracts for delivery of Issuer Securities and other derivative instruments.  Together to date, the funds have raised roughly $350 Million.

2022 Highlights:

• Aegis Special Situations QP Fund, LLC- Series Medtech IV (Aquyre Biosciences, Inc.) 
  Raised $4.8 Million
• Aegis Special Situations Fund, LLC- Series Medtech V 
  Raised $11.6 Million (Cordio Medical Ltd.)
• Aegis Special Situations Fund, LLC- Series Medtech VI 
  Raised $11.1 Million (Pristine Surgical LLC)
• Aegis Special Situations QP Fund, LLC- Series Medtech VI
  Raised $4.2 Million (Pristine Surgical LLC)
• Aegis Special Situations Fund, LLC- Series Medtech VII 
  Raised $4.3 Million (Orchestra BioMed, Inc.)
• Aegis Special Situations Fund, LLC- Series Medtech VIII
  Raised $4.2 Million (GT Metabolic Solutions, Inc.)
• Aegis Special Situations QP Fund, LLC- Series Medtech VIII 
  Raised $2.3 Million (GT Metabolic Solutions, Inc.)
• Aegis Special Situations Fund, LLC- Series Aerospace III 
  Raised $10.9 (Axiom Space, Inc.)
• Aegis Special Situations Fund, LLC- Series Medtech IX 
  Raised $8.7 (Diasome, Inc.) 
• Aegis Special Situations Fund, LLC- Series Medtech X
  Raised $5.9 (Momentis Surgical Ltd. (f/k/a Memic Innovative Surgery Ltd.)) 

2021 Highlights:

• Aegis Special Situations Fund, LLC- Series Agritech II (Indigo Ag, Inc.)
  Raised $9.6 Million
• Aegis Special Situations QP Fund, LLC- Series Agritech II (Indigo Ag, Inc.)
  Raised $5.1 Million
• Aegis Special Situations Fund, LLC- Series Fintech I (Chime)
  Raised $11.5 Million
• Aegis Special Situations Fund, LLC- Series Aerospace II (World View Enterprises, Inc.)
  Raised $4.4 Million
• Aegis Special Situations Fund, LLC- Series Medtech IV (Aquyre Biosciences, Inc.) 
  Raised $13.4 Million
• Aegis Special Situations Fund, LLC- Series Big Data II (ThoughtSpot, Inc.) 
  Raised $14.1 Million
• Aegis Special Situations Fund, LLC- Series Medtech V (Cordio Medical, Ltd.) 
  Raised $10.3 Million
• Aegis Special Situations Fund, LLC- Series Medtech VI (Pristine Surgical, LLC) 
  Raised $5.6 Million
• Aegis Special Situations Fund, LLC- Series HealthTech I (ZocDoc, Inc.)
  Raised $11.8 Million
• Aegis Special Situations Fund, LLC- Series Fintech III (Kraken)
  Raised $11.5 Million

2020 Highlights: 

• Aegis Special Situations Fund, LLC- Series Medtech I (DermaSensor, Inc.) 
  Raised $4.9 Million
• Aegis Special Situations Fund, LLC- Series Digital Freight Network I (Convoy)
  Raised $10.6 Million
• Aegis Special Situations Fund, LLC- Series Education II (Coursera)
  Raised $5.2 Million
• Aegis Special Situations Fund, LLC- Series Medtech II (Momentis Surgical Ltd. (f/k/a Memic Innovative Surgery Ltd.)) 
  Raised $17.9 Million
• Aegis Special Situations Fund, LLC- Series Medtech III (QinFlow) 
  Raised $7.8 Million

2019 Highlights:

• Aegis Special Situations Fund, LLC- Series Aerospace I (SpaceX) 
  Raised $5.2 Million
• Aegis Special Situations QP Fund, LLC- Series Aerospace I (SpaceX)
  Raised $2.2 Million
• Aegis Special Situations Fund, LLC- Series Big Data I (Palantir Technologies) 
  Raised $9.4 Million
• Aegis Special Situations Fund, LLC- Series Plant Protein I (Impossible Foods Inc.) 
  Raised $5.2 Million
• Aegis Special Situations QP Fund, LLC- Series Plant Protein I (Impossible Foods Inc.) 
  Raised $9.7 Million
• Aegis Special Situations Fund, LLC- Series Hospitality I (Airbnb, Inc.)
  Raised $2.4 Million
• Aegis Special Situations Fund, LLC- Series Agritech I (Hydrofarm Holdings Group, Inc.)
  Raised $4.9 Million
• Aegis Special Situations QP Fund, LLC- Series Agritech I (Hydrofarm Holdings Group, Inc.) 
  Raised $5.7 Million 
• Aegis Special Situations Fund, LLC- Series Fantasy Sports I (DraftKings Inc.) 
  Raised $3.6 Million 

2018 Highlights: 

• Aegis Special Situations Fund LLC, Series Rideshare I (DiDi Chuxing Technology Co.)
  Raised $10.7 Million
• Aegis Special Situations Fund, LLC- Series Education I (Udacity, Inc.)
  Raised $3.5 Million
• Aegis Special Situations Fund, LLC- Series DNA I (23andMe)
  Raised $5.3 Million
• Aegis Special Situations QP Fund, LLC- Series Hospitality I (Airbnb, Inc.)
  Raised $8.1 Million
• Aegis Special Situations QP Fund, LLC- Series Rideshare I (DiDi Chuxing Technology Co.)
  Raised $5.8 Million
• Aegis Special Situations Fund II, LLC – Series Rideshare I (Lyft, Inc.)
  Raised $11.8 Million 

Tech Insight Partners LLC is a Delaware series limited liability company created for the purpose of making and managing investments in InSightec Ltd., a private company advancing MR-guided focused ultrasound. 

2020 Highlights: 

• Tech Insight Partners, LLC- Series B (INSIGHTEC, Ltd.)
  Raised $3.7 Million
• Tech Insight Partners, LLC- Series C (INSIGHTEC, Ltd.)
  Raised $6.2 Million

2018 Highlights: 

• Tech Insight Partners, LLC- Series A (INSIGHTEC, Ltd.)
  Raised $5.5 Million

DarioHealth Corp. (Nasdaq: DRIO) is a leading, global digital therapeutics company revolutionizing the way people with chronic conditions manage their health. By delivering evidence-based interventions that are driven by data, high-quality software and coaching, we empower individuals to make healthy adjustments to their daily lifestyle choices to improve their overall health. Our cross-functional team operates at the intersection of life sciences, behavioral science and software technology to deliver highly engaging therapeutic interventions. Dario is one of the highest-rated diabetes solutions in the market, and its user-centric MyDario™ mobile app is loved by tens of thousands of consumers around the globe. DarioHealth is rapidly moving into new chronic conditions and geographic markets, using a performance-based approach to improve the health of users managing chronic disease.

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) is a clinical stage biopharmaceutical company, focused on the development and commercialization of novel therapeutics to treat rare life-threatening ("orphan") inflammatory-fibrotic diseases with clear unmet medical needs. Its lead product Resunab^TM is a novel oral anti-inflammatory drug that is expected to commence Phase IIa clinical trials for the treatment of cystic fibrosis and diffuse scleroderma, pending U.S. Food and Drug Administration (FDA) approval of the Investigational New Drug Applications (INDs), expected to be filed in the second half of 2014.

Organovo Holdings, Inc. (NYSE:ONVO) is a 3D human biology company, focused on the discovery and development of human tissues that recapitulate native tissue architecture and function, for use in drug discovery and, ultimately, as regenerative medicine products.

INSIGHTEC is the world leader and innovator of MRI-guided Focused Ultrasound. The company's non-invasive therapy platforms, Exablate and Exablate Neuro, are proven technology based on sound clinical evidence for treating essential tremor, painful bone metastases and uterine fibroids. The company is dedicated to improving patient lives by collaborating with physicians, medical institutions, academic researchers and regulatory bodies around the world. INSIGHTEC is headquartered in Haifa, Israel, and Miami, with offices in Dallas, Tokyo and Shanghai.

2021 Highlights: 

• Agritech Partners, LLC- Series HB-1 (Hydrobuilder Holdings, Inc.)
  Raised $6.6 Million
• Agritech QP Partners, LLC- Series HB-1 (Hydrobuilder Holdings, Inc.)
  Raised $21.8 Milllion